THE GENETIC AND FUNCTIONAL BASIS OF HIV-1 RESISTANCE TO NONNUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITORS

被引:0
|
作者
EMINI, EA
BYRNES, VW
CONDRA, JH
SCHLEIF, WA
SARDANA, VV
机构
关键词
D O I
暂无
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The nonnucleoside reverse transcriptase (RT) inhibitors are structurally diverse compounds that are specific inhibitors of the human immunodeficiency virus type 1 RT enzyme. The compounds are largely functionally identical and bind to a common site in the enzyme. HIV-1 variants that exhibit reduced susceptibility to these inhibitors have been derived in cell culture and, more recently, from HIV-1-infected patients undergoing experimental therapy. The variants express amino acid substitutions at RT positions that apparently interact directly with the inhibitors. Effects of specific substitutions at these positions vary among the compounds, suggesting subtle differences in how the compounds physically interact with the enzyme.
引用
收藏
页码:11 / 17
页数:7
相关论文
共 50 条
  • [21] NOVEL NONNUCLEOSIDE INHIBITORS OF HIV-1 REVERSE-TRANSCRIPTASE .2. TRICYCLIC PYRIDOBENZOXAZEPINONES AND DIBENZOXAZEPINONES
    KLUNDER, JM
    HARGRAVE, KD
    WEST, MA
    CULLEN, E
    PAL, K
    BEHNKE, ML
    KAPADIA, SR
    MCNEIL, DW
    WU, JC
    CHOW, GC
    ADAMS, J
    JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (10) : 1887 - 1897
  • [22] PRELIMINARY STRUCTURAL-ANALYSIS OF THE MUTATIONS SELECTED BY NONNUCLEOSIDE INHIBITORS OF HIV-1 REVERSE-TRANSCRIPTASE
    TONG, L
    CARDOZO, M
    JONES, PJ
    ADAMS, J
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1993, 3 (04) : 721 - 726
  • [23] PREVENTION OF HIV-1 INFECTION IN CHIMPANZEES BY A NONNUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITOR
    SCHLEIF, WA
    SARDANA, VV
    BYRNES, VW
    MURTHY, KK
    EMINI, EA
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 23 - 23
  • [24] Use of nonnucleoside reverse-transcriptase inhibitors
    Holtzer, CD
    Coleman, RL
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1998, 55 (03) : 283 - 287
  • [25] RESISTANCE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) TO NONNUCLEOSIDE HIV-1-SPECIFIC REVERSE-TRANSCRIPTASE INHIBITORS
    DECLERCQ, E
    INTERNATIONAL JOURNAL OF IMMUNOTHERAPY, 1994, 10 (04): : 145 - 158
  • [26] HIV RESISTANCE TO REVERSE-TRANSCRIPTASE INHIBITORS
    DECLERCQ, E
    BIOCHEMICAL PHARMACOLOGY, 1994, 47 (02) : 155 - 169
  • [27] MOLECULAR MODELING OF HIV-1 REVERSE-TRANSCRIPTASE INHIBITORS
    CRABBE, MJC
    FALKINGBRIDGE, SS
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1991, 7 (03) : 261 - 264
  • [28] CARBOXANILIDE DERIVATIVE NONNUCLEOSIDE INHIBITORS OF HIV-1 REVERSE-TRANSCRIPTASE INTERACT WITH DIFFERENT MECHANISTIC FORMS OF THE ENZYME
    FLETCHER, RS
    SYED, K
    MITHANI, S
    DMITRIENKO, GI
    PARNIAK, MA
    BIOCHEMISTRY, 1995, 34 (13) : 4346 - 4353
  • [29] NONNUCLEOSIDE INHIBITORS OF HIV-1 REVERSE-TRANSCRIPTASE - MOLECULAR MODELING AND X-RAY STRUCTURE INVESTIGATIONS
    SCHAFER, W
    FRIEBE, WG
    LEINERT, H
    MERTENS, A
    POLL, T
    VONDERSAAL, W
    ZILCH, H
    NUBER, B
    ZIEGLER, ML
    JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (06) : 726 - 732
  • [30] Disubstituted uracils as novel nonnucleoside inhibitors of HIV-1 reverse transcriptase inhibitors
    Valuev-Elliston, V.
    Babkov, D.
    Paramonova, M.
    Ivanov, A.
    Kochetkov, S.
    FEBS JOURNAL, 2013, 280 : 370 - 370